Document is current
Any future updates will be listed below
-
Authors
Starkey Lewis, Philip J.
Cartwright, Jennifer A. https://orcid.org/0000-0003-1143-9011
Campana, Lara
Baumgarten, Birgit U.
Ebersbach, Hilmar
Ludwig, Marie-Gabrielle
Marszalek, Gregory
Stutchfield, Benjamin
Aird, Rhona
Man, Tak-Yung
O’Duibhir, Eoghan
Seuwen, Klaus
Forbes, Stuart J.
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (R83519)
Wellcome Trust (108906/Z/15/Z)
Medical Research Council (MR/J010766/1)
- License Information
-
More Information
Article History
Received: 30 March 2026
Accepted: 10 June 2026
First Online: 25 June 2026
Declarations
:
: All animal experiments were carried out under procedural guide lines, severity protocols and with ethical permission from the University of Edinburgh Animal Welfare and Ethical Review Body and the Home Office (UK), licence numbers 70/7847 and P231C5F81.
: There was no competing interests at the time of experiments, however L.C., P.S.L., and S.J.F are shareholders of Resolution Therapeutics Ltd. a macrophage cell therapy developer. S.J.F is a scientific adviser and L.C. is an employee of Resolution Therapeutics.
